ASOPRS 2021 - Physician's Weekly



Take Our ASOPRS Quiz!

The ASOPRS 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly. The ASOPRS 2022...

The Impact on Ocular Surface Disease of Teprotumumab for TED

We recently spoke with Andrea Lora Kossler, MD, FACS, from the Byers Eye Institute at Stanford University about results from the study “Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease,” which she...

Monotherapy for Dysthyroid Optic Neuropathy

Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...

Teprotumumab for Long-Standing, Active TED

While phase II and III trials indicate that teprotumumab therapy can significantly reduce proptosis and Clinical Activity Score (CAS) in patients with recent-onset (< 8 months), untreated TED (except for steroid therapy >...

Recalcitrant TED Responsive to Teprotumumab

New research presented at the American Society of Ophthalmic Plastic & Reconstructive Surgery’s fall symposium highlighted the benefits of Tepezza (teprotumumab) for patients with thyroid eye and Graves disease....



For latest news and updates
Email-id is invalid